Skip to content

#BMS

Today 0 items
Oct 8Thu
  1. biospace.com40

    Q3 layoffs down YOY, with 90% fewer biopharma employees affected

    BioSpace tallies show biopharma layoffs fell sharply year over year in Q3, with a 56% drop in companies making or projecting cuts and a 90% plunge in affected employees; the 27 companies and 2,568 people affected are the lowest quarterly figures since tracking began in 2024. Eight Big Pharma companies accounted for cuts of 1,845 employees in the quarter, including Bristol Myers Squibb letting go of 265 people in Princeton, New Jersey, GSK closing a German vaccine site with about 650 job losses, and Novartis, whose 2026 disclosures total at least 922 people. Novo CEO Mike Maziar Doustdar said overall headcount has dropped by 13,000 over the past year, including 9,000 layoffs under a restructuring announced in September 2025 targeting around $1.25 billion in annualized savings.

Sep 30Wed
  1. biospace.com40

    GSK laying off 1.2K+ in Belgium

    GSK is laying off more than 1,200 employees in Belgium, part of a wave of biopharma job cuts in 2026 tracked by BioSpace. Other reductions include Novo Nordisk's workforce shrinking by about 13,000 people over the past year to 67,000 as it shifts money into R&D, Takeda cutting over 4,700 jobs, and Bristol Myers Squibb terminating 265 employees at its Princeton, New Jersey site between Dec. 17, 2026 and May 21, 2027. Layoffs tied to M&A include BioNTech letting go of around 800 people at CureVac.

Sep 3Thu
  1. fiercebiotech.com64

    GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

    GSK has licensed Hutchmed's preclinical KRAS-EGFR antibody conjugate HMPL-A830, paying $110 million upfront in a deal worth up to $1.295 billion, excluding Mainland China, Hong Kong, Macau and Taiwan. The candidate delivers a KRAS inhibitor to EGFR-expressing tumors and is slated to enter trials later this year, initially in colorectal, pancreatic and lung cancer. Hutchmed will run Phase 1 trials, after which GSK takes over R&D and commercialization outside select Asian territories.

    Why it matters: GSK is paying up to $1.295 billion for a preclinical first-in-class KRAS-EGFR candidate, a notable early-stage oncology licensing deal.

Aug 14Fri
  1. FiercePharma48

    It's BMS vs. Celgene investors once more after US appeals court revives lawsuit

    A U.S. appeals court in Manhattan has revived a lawsuit by Celgene shareholders who accuse Bristol Myers Squibb of deliberately slowing the FDA approval of Breyanzi to avoid paying more than $6 billion under a contingent value rights deal tied to its $74 billion acquisition of Celgene in 2019. The 3-0 ruling overturned Judge Jesse Furman's 2024 dismissal and found that trustee UMB Bank can maintain the suit because BMS accepted its appointment. A related breach-of-contract case was allowed to proceed in part in December, and it is uncertain how the decision affects it.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org